QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
NASDAQ:DRRX

DURECT - DRRX Stock Forecast, Price & News

$5.80
-0.60 (-9.38%)
(As of 02/6/2023 05:33 PM ET)
Add
Compare
Today's Range
$5.65
$6.28
50-Day Range
$3.39
$8.72
52-Week Range
$3.16
$9.70
Volume
260,829 shs
Average Volume
112,935 shs
Market Capitalization
$132.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.00

DURECT MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
452.7% Upside
$32.00 Price Target
Short Interest
Bearish
1.43% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.19
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.62) to ($1.71) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.36 out of 5 stars

Medical Sector

968th out of 1,027 stocks

Pharmaceutical Preparations Industry

469th out of 500 stocks

DRRX stock logo

About DURECT (NASDAQ:DRRX) Stock

DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.

Receive DRRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter.

DRRX Stock News Headlines

Durect (NASDAQ: DRRX)
New "Vertical" Technology Solves Solar Power's Major Flaw
Even conservationists hate conventional solar farms. That's because they take up too much land and can degrade the environment. And let's face it, land is expensive...Fortunately, new groundbreaking tower technology solves solar's #1 drawback. These unique vertical structures not only take up to 90% less land space, but also generate extra electric power.
DURECT Announces 1-for-10 Reverse Stock Split
DURECT (NASDAQ:DRRX) Research Coverage Started at StockNews.com
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Innocoll and DURECT Announce U.S. launch of POSIMIR®
See More Headlines
Receive DRRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter.

DRRX Company Calendar

Last Earnings
11/01/2021
Today
2/06/2023
Next Earnings (Estimated)
3/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DRRX
Employees
79
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$32.00
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$32.00
Forecasted Upside/Downside
+451.7%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-36,260,000.00
Net Margins
-136.99%
Pretax Margin
-136.99%

Debt

Sales & Book Value

Annual Sales
$13.98 million
Book Value
$2.54 per share

Miscellaneous

Free Float
21,761,000
Market Cap
$132.18 million
Optionable
Optionable
Beta
1.40

Key Executives

  • James E. Brown
    President, Chief Executive Officer & Director
  • Judy R. Joice
    Senior VP-Operations & Corporate Quality Assurance
  • Timothy M Papp
    Chief Financial Officer & Secretary
  • Wei Qi Lin
    Executive Vice President-Research & Development
  • David J. Ellis
    Vice President-Clinical Development













DRRX Stock - Frequently Asked Questions

What is DURECT's stock price forecast for 2023?

0 Wall Street research analysts have issued 1-year price objectives for DURECT's stock. Their DRRX share price forecasts range from $32.00 to $32.00. On average, they predict the company's stock price to reach $32.00 in the next twelve months. This suggests a possible upside of 451.7% from the stock's current price.
View analysts price targets for DRRX
or view top-rated stocks among Wall Street analysts.

How have DRRX shares performed in 2023?

DURECT's stock was trading at $3.46 at the beginning of the year. Since then, DRRX shares have increased by 67.6% and is now trading at $5.80.
View the best growth stocks for 2023 here
.

When is DURECT's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 6th 2023.
View our DRRX earnings forecast
.

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) released its quarterly earnings data on Monday, November, 1st. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.10. The specialty pharmaceutical company earned $2.17 million during the quarter, compared to the consensus estimate of $2.18 million. DURECT had a negative net margin of 136.99% and a negative trailing twelve-month return on equity of 72.05%. During the same quarter last year, the company earned ($0.50) earnings per share.

When did DURECT's stock split?

DURECT shares reverse split on the morning of Tuesday, December 6th 2022. The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of DURECT own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM).

What is DURECT's stock symbol?

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

Who are DURECT's major shareholders?

DURECT's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (4.01%), Ironwood Investment Management LLC (0.37%), Cowen Prime Advisors LLC (0.21%), DAVENPORT & Co LLC (0.07%), Regis Management CO LLC (0.06%) and Merit Financial Group LLC (0.04%). Insiders that own company stock include Gail J Maderis, Gail M Farfel, Judith J Robertson, Judy R Joice, Lp Bleichroeder, Mohammad Azab and Simon X Benito.
View institutional ownership trends
.

How do I buy shares of DURECT?

Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DURECT's stock price today?

One share of DRRX stock can currently be purchased for approximately $5.80.

How much money does DURECT make?

DURECT (NASDAQ:DRRX) has a market capitalization of $132.18 million and generates $13.98 million in revenue each year. The specialty pharmaceutical company earns $-36,260,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis.

How can I contact DURECT?

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The official website for the company is www.durect.com. The specialty pharmaceutical company can be reached via phone at (408) 777-1417, via email at mike.arenberg@durect.com, or via fax at 408-777-3577.

This page (NASDAQ:DRRX) was last updated on 2/6/2023 by MarketBeat.com Staff